Celgene Prices $8 Billion of Senior Unsecured Notes
August 04 2015 - 7:30AM
Business Wire
Celgene Corporation (NASDAQ:CELG) today announced the
successful pricing of five series of senior unsecured notes for an
aggregate principal amount of $8.0 billion. Of these notes, $1.0
billion will mature in 2018 and will bear interest at an annual
rate of 2.125 percent, $1.5 billion will mature in 2020 and will
bear interest at an annual rate of 2.875 percent, $1.0 billion will
mature in 2022 and will bear interest at an annual rate of 3.550
percent, $2.5 billion will mature in 2025 and will bear interest at
an annual rate of 3.875 percent and $2.0 billion will mature in
2045 and will bear interest at an annual rate of 5.000 percent. The
2.125 percent notes due 2018, the 2.875 percent notes due 2020, the
3.550 percent notes due in 2022, the 3.875 percent notes due in
2025 and the 5.000 percent notes due in 2045 were priced to yield
2.127 percent, 2.914 percent, 3.594 percent, 3.993 percent and
5.020 percent, respectively.
Celgene expects to use the net proceeds from the offering to
finance a portion of the acquisition of Receptos, Inc. and the
remainder for general corporate purposes, which may include,
without limitation, further development of Celgene’s clinical and
pre-clinical programs, capital expenditures, general corporate
development activities, meeting working capital needs, share
repurchases of Celgene’s common stock and repayment of some or all
of Celgene’s outstanding commercial paper. The offering is expected
to close on August 12, 2015.
J.P. Morgan Securities LLC, Citigroup Global Markets Inc.,
Deutsche Bank Securities Inc. and Merrill Lynch, Pierce, Fenner
& Smith Incorporated acted as joint book-running managers and
representatives of the several underwriters. A copy of the
preliminary prospectus supplement and the accompanying base
prospectus, which is filed as part of Celgene’s effective shelf
registration statement on Form S-3 filed on October 30, 2013 (File
No. 333-191998), may be obtained from any of the representatives by
calling J.P. Morgan Securities LLC collect at 212-834-4533,
Citigroup Global Markets Inc. at 1-800-831-9146, Deutsche Bank
Securities Inc. at 1-800-503-4611 and Merrill Lynch, Pierce, Fenner
& Smith Incorporated at 1-800-294-1322.
An electronic copy of the prospectus supplement and the
accompanying base prospectus may also be obtained at no charge at
the Securities and Exchange Commission’s website at
www.sec.gov.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the notes described herein, nor
shall there be any sale of these notes in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the laws of such
jurisdiction. The offering of the notes will be made only by means
of a prospectus supplement and the accompanying base
prospectus.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in
the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through gene and protein regulation.
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," “outlook” and similar expressions. Forward-looking
statements are based on management’s current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and our other reports filed with the Securities
and Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150804005898/en/
Celgene CorporationPeter N. Kellogg, 908-673-9811EVP,
Chief Financial OfficerorPatrick E. Flanigan III, 908-673-9969VP,
Investor Relations
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024